NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of NovoCure Limited (NASDAQ:NVCR) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $25.50.

Several equities research analysts have recently commented on NVCR shares. Wedbush reaffirmed an “outperform” rating and set a $24.00 price target on shares of NovoCure in a research report on Thursday, July 25th. Wells Fargo & Company reduced their target price on shares of NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, July 26th. HC Wainwright lifted their price target on shares of NovoCure from $22.00 to $24.00 and gave the stock a “neutral” rating in a research note on Friday, July 26th. Finally, Evercore ISI boosted their price objective on shares of NovoCure from $14.50 to $20.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd.

Hedge Funds Weigh In On NovoCure

Several large investors have recently added to or reduced their stakes in NVCR. Ridgewood Investments LLC purchased a new stake in shares of NovoCure in the second quarter worth $28,000. Signaturefd LLC boosted its holdings in NovoCure by 61.7% in the 2nd quarter. Signaturefd LLC now owns 1,644 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 627 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in NovoCure in the 2nd quarter worth $34,000. Fifth Third Bancorp purchased a new stake in NovoCure in the 2nd quarter worth $43,000. Finally, GAMMA Investing LLC raised its holdings in NovoCure by 278.0% during the first quarter. GAMMA Investing LLC now owns 2,880 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 2,118 shares during the period. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Trading Down 1.6 %

NASDAQ:NVCR opened at $19.44 on Monday. The company has a 50 day simple moving average of $18.55 and a two-hundred day simple moving average of $17.42. The company has a market cap of $2.10 billion, a PE ratio of -10.74 and a beta of 0.70. The company has a current ratio of 6.46, a quick ratio of 6.22 and a debt-to-equity ratio of 1.81. NovoCure has a 12 month low of $10.87 and a 12 month high of $24.74.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.09. The company had revenue of $150.40 million during the quarter, compared to analysts’ expectations of $135.83 million. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. NovoCure’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.54) earnings per share. Research analysts forecast that NovoCure will post -1.34 earnings per share for the current year.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.